Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is male or non-pregnant female, 9 years of age or older. Females must be post-menopausal, surgically sterile, or using highly effective birth control methods. Women of child-bearing potential must have a negative urine pregnancy test (UPT) at the Screening/Baseline Visit.~2. Subject has provided written and verbal informed consent/assent. A subject under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing.~3. Subject has an Investigator's Global Assessment (IGA) score of 3 (moderate) or 4 (severe) \[0 (clear) to 4 (severe) scale\].~4. Subject has facial acne vulgaris with at least 30 to a maximum of 75 inflammatory lesions (papules, pustules, and nodules) and 30 to a maximum of 100 non-inflammatory lesions (open and closed comedones).~5. Subject and parent/guardian (if applicable) are willing to comply with study instructions and return to the clinic for required visits.~6. Subject has used the same type and brand of make-up, other facial products (exclusive of RX/OTC acne cleansers) and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at least one (1) month prior to the Baseline Visit and agrees to continue his/her other general skin and hair care products and regimen for the entire study.~Exclusion Criteria:~1. Subject is pregnant, lactating, or is planning to become pregnant during the study.~2. Subject has any skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topical or systemic therapy.~3. Subject has greater than two (2) facial nodules.~4. Subject has nodulocystic acne.~5. Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.~6. Subject is currently enrolled in an investigational drug or device study.~7. Subject has received an investigational drug or has been treated with an investigational device within 30 days prior to the initiation of treatment (Baseline).~8. Subject has facial hair that could interfere with the study assessments in the opinion of the investigator.~9. Subject and parent/guardian (if applicable) are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.~10. Subject may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits.~11. Subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles.~12. Subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the trial.~13. Subject has used any of the prohibited topical anti-acne treatments or procedures prior to the study unless appropriate washout period is documented.~14. Subject has used used any of the prohibited systemic anti-acne medications prior to the study unless appropriate washout period is documented.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CB-03-01 cream (Type: EXPERIMENTAL): CB-03-01 cream, 1% applied twice daily for 12 weeks
- Vehicle cream (Type: PLACEBO_COMPARATOR): Vehicle cream applied twice daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete